Gossamer Bio, Inc. (GOSS)
| Market Cap | 80.64M -59.5% |
| Revenue (ttm) | 48.47M -57.7% |
| Net Income | -170.37M |
| EPS | -0.75 |
| Shares Out | 234.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,318,188 |
| Open | 0.3409 |
| Previous Close | 0.3406 |
| Day's Range | 0.3300 - 0.3550 |
| 52-Week Range | 0.3142 - 3.8700 |
| Beta | 2.15 |
| Analysts | Buy |
| Price Target | 4.19 (+1,119.44%) |
| Earnings Date | May 26, 2026 |
About GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup comp... [Read more]
Financial Performance
In 2025, Gossamer Bio's revenue was $48.47 million, a decrease of -57.74% compared to the previous year's $114.70 million. Losses were -$170.37 million, 201.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for GOSS stock is "Buy." The 12-month stock price target is $4.19, which is an increase of 1,119.44% from the latest price.
News
GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: ...
Gossamer Bio, Inc. (GOSS) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - April 20, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" ...
Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald on Friday downgraded Gossamer Bio (GOSS) to Neutral from Overweight without a price target The firm cites the negative Phase 3 readout for PROSERA and an unclear regulatory…
Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded Gossamer Bio (GOSS) to Neutral from Overweight.
Gossamer Bio reports Q4 EPS (21c), consensus (20c)
Reports Q4 revenue $13.799M, consensus $7.52M. “Following our PROSERA topline results, we are focused on fully understanding the PROSERA dataset, engaging with the FDA, and evaluating strategic option...
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hyper...
Gossamer Bio options imply 46.1% move in share price post-earnings
Pre-earnings options volume in Gossamer Bio (GOSS) is normal with puts leading calls 19:3. Implied volatility suggests the market is anticipating a move near 46.1%, or 0c, after results are…
Gossamer Bio price target lowered to $5 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Gossamer Bio (GOSS) to $5 from $10 and keeps a Buy rating on the shares. The firm reduced its probability of success…
Gossamer Bio price target lowered to $3 from $12 at Oppenheimer
Oppenheimer lowered the firm’s price target on Gossamer Bio (GOSS) to $3 from $12 and keeps an Outperform rating on the shares. The firm came away more positive on seralutinib/PAH,…
Gossamer Bio downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Gossamer Bio (GOSS) to Neutral from Buy with a price target of 50c, down from $8. The firm notes the company’s Phase 3 PROSERA topline results, which…
Wedbush downgrades Gossamer Bio to Neutral, lowers target to $1
As previously reported, Wedbush downgraded Gossamer Bio (GOSS) to Neutral from Outperform with a price target of $1, down from $6. The firm notes that the PROSERA study results came…
Gossamer Bio downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Gossamer Bio (GOSS) to Neutral from Outperform with a price target of $1, down from $6.
Gossamer Bio downgraded to Market Perform from Outperform at Leerink
Leerink last night downgraded Gossamer Bio (GOSS) to Market Perform from Outperform with a price target of $1, down from $6. The company announced “disappointing” Phase 3 PROSERA results, missing…
Gossamer Bio downgraded to Underweight from Overweight at Barclays
Barclays double downgraded Gossamer Bio (GOSS) to Underweight from Overweight with a price target of 30c, down from $9. The company’s Phase 3 pulmonary arterial hypertension highlights the challenges ...
Gossamer Bio downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Gossamer Bio (GOSS) to Market Perform from Outperform with a price target of $1, down from $6.
Gossamer Bio downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Gossamer Bio (GOSS) to Market Perform from Outperform with a price target of $1, down from $6.
Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Gossamer Bio, Inc. (NASDAQ: GOSS). The investigation focuses on Gossamer's...
Gossamer Bio Transcript: Study result
The PROSERA phase III trial in PAH showed seralutinib improved 6MWD but narrowly missed statistical significance in the overall population due to a high placebo response, especially in Latin America. Clinically meaningful and statistically significant benefits were observed in high-risk and CTD subgroups, with a manageable safety profile.
Gossamer Bio's experimental lung condition drug fails in late-stage trial
Gossamer Bio said on Monday its experimental drug missed the main goal of a late-stage study in patients with a serious lung and heart condition.
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS) a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypert...
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul...
Gossamer Bio to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul...
Gossamer Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Seralutinib’s phase 3 Prosera trial is set for a key data readout in February, with a focus on sicker patients and a differentiated safety profile. Commercial launch is targeted for late Q2 2027, with expansion into PH-ILD and a strengthened pipeline through recent asset acquisition.
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm...
Gossamer Bio Transcript: Emerging Growth Conference
Major phase 3 data for seralutinib in PAH is expected in February, with a second phase 3 in PH-ILD planned by year-end, targeting a combined market over $20 billion. Seralutinib's strong safety and efficacy profile, plus the addition of RT234, positions the pipeline for global leadership.